Thyroid Cancer

Latest News

Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Selpercatinib Earns Full FDA Approval Status in RET+ Thyroid Cancer

June 12th 2024

Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.

Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
Selpercatinib Earns Accelerated Approval in Pediatric RET+ Thyroid Cancer

May 29th 2024

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.
FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC

May 15th 2024

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.
Setanaxib/Pembrolizumab Improves Survival in Head and Neck Cancer

May 8th 2024

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.
Eftilagimod Alpha/Pembrolizumab Elicits Encouraging Responses in HNSCC

April 25th 2024

More News